Ono Pharmaceutical Co., Ltd.
189
14
47
126
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
4.8%
9 terminated/withdrawn out of 189 trials
93.3%
+6.8% vs industry average
30%
56 trials in Phase 3/4
41%
52 of 126 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (189)
A Study to Investigate the Pharmacokinetics of Tirabrutinib in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Healthy Participants
Role: lead
A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer
Role: collaborator
Nivolumab Plus Lenvatinib Against Anaplastic Thyroid Cancer (NAVIGATION)
Role: collaborator
A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy
Role: lead
A Clinical Study of ONO-1110 in Patients With Hunner Type Interstitial Cystitis
Role: lead
Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study)
Role: lead
A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer
Role: lead
A Clinical Study of ONO-1110 in Patients With Fibromyalgia
Role: lead
Study of ONO-7475 in Combination With Osimertinib in EGFR Gene Mutation-positive Non-small Cell Lung Cancer
Role: lead
A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)
Role: lead
Study to ONO-4538 in Patients With Rhabdoid Tumor
Role: lead
IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)
Role: lead
Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer
Role: collaborator
A Study of ONO-1110 in Patients With Postherpetic Neuralgia
Role: lead
A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV)
Role: lead
A Study of ONO-1110 in Patients With Social Anxiety Disorder
Role: lead
A Study of ONO-1110 in Patients With Major Depressive Disorder
Role: lead
A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin
Role: collaborator
Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma
Role: lead
ONO-4538 Study in Patients With Richter's Transformation
Role: lead